Dr. Reddy's launches Fosaprepitant Injection in US

11 Sep 2019 Evaluate

Dr. Reddy's Laboratories has launched Fosaprepitant Injection in the U.S. Market, the therapeutic generic equivalent of EMEND (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).

The EMEND for Injection brand had U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.

Dr. Reddy's Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1218.40 9.95 (0.82%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×